Why do we not have an HIV vaccine and how can we make one?
- PMID: 9585194
- DOI: 10.1038/nm0598supp-495
Why do we not have an HIV vaccine and how can we make one?
Comment in
-
Vaccine reactions.Nat Med. 1998 Jul;4(7):746. doi: 10.1038/nm0798-746a. Nat Med. 1998. PMID: 9662343 No abstract available.
-
Vaccine reactions.Nat Med. 1998 Jul;4(7):746. doi: 10.1038/nm0798-746c. Nat Med. 1998. PMID: 9662345 No abstract available.
Similar articles
-
HIV vaccines--where are we going?Nat Med. 1998 May;4(5 Suppl):532-4. doi: 10.1038/nm0598supp-532. Nat Med. 1998. PMID: 9585205 Review. No abstract available.
-
Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.Arch Virol. 2004 Sep;149(9):1705-20. doi: 10.1007/s00705-004-0333-8. Arch Virol. 2004. PMID: 15593414
-
SIV vaccine for AIDS.Science. 1998 Jan 2;279(5347):14-5. doi: 10.1126/science.279.5347.10i. Science. 1998. PMID: 9441400 No abstract available.
-
AIDS 1995. Vaccines and immunology: overview.AIDS. 1995;9 Suppl A:S111-2. AIDS. 1995. PMID: 8819577 No abstract available.
-
[HIV vaccine].Nihon Rinsho. 2005 May;63 Suppl 5:659-65. Nihon Rinsho. 2005. PMID: 15954426 Review. Japanese. No abstract available.
Cited by
-
Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.J Virol. 2005 Apr;79(8):4927-35. doi: 10.1128/JVI.79.8.4927-4935.2005. J Virol. 2005. PMID: 15795278 Free PMC article.
-
Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.J Virol. 2000 May;74(10):4746-54. doi: 10.1128/jvi.74.10.4746-4754.2000. J Virol. 2000. PMID: 10775613 Free PMC article.
-
Inhibition of HIV-1 infection by monoclonal antibodies to carbohydrates of Schistosoma mansoni.Med Microbiol Immunol. 2005 Jan;194(1-2):61-5. doi: 10.1007/s00430-003-0214-x. Med Microbiol Immunol. 2005. PMID: 14634805
-
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.J Immunol. 2009 Mar 15;182(6):3718-27. doi: 10.4049/jimmunol.0803115. J Immunol. 2009. PMID: 19265150 Free PMC article.
-
Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.J Virol. 2003 Nov;77(21):11385-97. doi: 10.1128/jvi.77.21.11385-11397.2003. J Virol. 2003. PMID: 14557624 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources